In the follow-up study of the same cohort at one year, Ghani et al. reported statistically significant improvements in fasting plasma glucose compared to the those who received CHDR at one year, but only for women who had higher baseline fasting insulin levels (indicating a degree of persisting insulin resistance): the low GI group had a 2.2% reduction from the baseline in FBG (−0.12 ± 0.27 mmol l−1 ), whereas CHDR subjects had a 3.8% increase (0.17 ± 0.32 mmol l−1) (p = 0.025) [70]. This evidence concerns the gene INS and Insulin resistance.